Overview

Drug Interaction Study of MGL-3196 With Pioglitazone

Status:
Completed
Trial end date:
2019-01-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Madrigal Pharmaceuticals, Inc.
Treatments:
Pioglitazone